<DOC>
	<DOCNO>NCT03054545</DOCNO>
	<brief_summary>This study evaluate efficacy safety novel chemical synthetic agent iguratimod treatment refractory lupus nephritis . All subject least one fail immunosuppressive treatment suffer active nephritis screening stage . The study period 52 week . All subject receive therapy iguratimod combine steroid .</brief_summary>
	<brief_title>Iguratimod Treatment Refractory Lupus Nephritis</brief_title>
	<detailed_description />
	<mesh_term>Nephritis</mesh_term>
	<mesh_term>Lupus Nephritis</mesh_term>
	<criteria>Active lupus nephritis : Fulfill ACR classification criterion ( 2009 ) SLE Proteinuria ≥1g/24h screen stage experience least one fail therapy within one year screening , include limit cyclophosphamide , methotrexate , azathioprine , mycophenolate mofetil , cyclosporin , tacrolimus leflunomide . The regime monotherapy combination . Any regime least apply six month . Body weight ≥40kg SLE2K score ≥8 Agreement contraception Informed consent obtain Active severe SLEdriven renal disease unstable renal disease screen Active severe unstable neuropsychiatric SLE Clinically significant active infection include ongoing chronic infection History human immunodeficiency virus ( HIV ) Confirmed Positive test hepatitis B positive test hepatitis C Active tuberculosis Live attenuate vaccine within 4 week prior screen Subjects significant hematologic abnormality Abnormal liver function test screening ( ALT , AST total bilirubin 2 fold upper normal level History peptic ulcer GI bleeding ; treatment warfarin anticoagulant within last 14 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>